150 related articles for article (PubMed ID: 25016807)
1. [Small molecular compounds for BCR/ABL-negative myeloproliferative neoplasms].
Nagai T
Nihon Rinsho; 2014 Jun; 72(6):1073-8. PubMed ID: 25016807
[TBL] [Abstract][Full Text] [Related]
2. [Not Available].
Soret J; Kiladjian JJ
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S29-38. PubMed ID: 27494970
[TBL] [Abstract][Full Text] [Related]
3. Expansion of a BCR-ABL clone in a JAK2 V617F myeloproliferative neoplasm treated by ruxolitinib.
Luque Paz D; Ianotto JC; Chauveau A; Guibourg B; Lecucq L; Lippert E; Ugo V
Ann Hematol; 2016 Jan; 95(2):349-50. PubMed ID: 26459144
[No Abstract] [Full Text] [Related]
4. Combination treatment for myeloproliferative neoplasms using JAK and pan-class I PI3K inhibitors.
Choong ML; Pecquet C; Pendharkar V; Diaconu CC; Yong JW; Tai SJ; Wang SF; Defour JP; Sangthongpitag K; Villeval JL; Vainchenker W; Constantinescu SN; Lee MA
J Cell Mol Med; 2013 Nov; 17(11):1397-409. PubMed ID: 24251790
[TBL] [Abstract][Full Text] [Related]
5. The promise of Janus kinase inhibitors in the treatment of hematological malignancies.
Senkevitch E; Durum S
Cytokine; 2017 Oct; 98():33-41. PubMed ID: 28277287
[TBL] [Abstract][Full Text] [Related]
6. JAK inhibitors: pharmacology and clinical activity in chronic myeloprolipherative neoplasms.
Treliński J; Robak T
Curr Med Chem; 2013; 20(9):1147-61. PubMed ID: 23317159
[TBL] [Abstract][Full Text] [Related]
7. Underlying mechanisms of the JAK2V617F mutation in the pathogenesis of myeloproliferative neoplasms.
Mullally A
Pathologe; 2016 Nov; 37(Suppl 2):175-179. PubMed ID: 27796499
[TBL] [Abstract][Full Text] [Related]
8. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK1/2 inhibitors in the treatment of chronic myeloproliferative neoplasms.
Keohane C; Mesa R; Harrison C
Am Soc Clin Oncol Educ Book; 2013; ():301-5. PubMed ID: 23714529
[TBL] [Abstract][Full Text] [Related]
10. JAK1/2 and Pan-deacetylase inhibitor combination therapy yields improved efficacy in preclinical mouse models of JAK2V617F-driven disease.
Evrot E; Ebel N; Romanet V; Roelli C; Andraos R; Qian Z; Dölemeyer A; Dammassa E; Sterker D; Cozens R; Hofmann F; Murakami M; Baffert F; Radimerski T
Clin Cancer Res; 2013 Nov; 19(22):6230-41. PubMed ID: 24081976
[TBL] [Abstract][Full Text] [Related]
11. Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.
Bhagwat N; Koppikar P; Keller M; Marubayashi S; Shank K; Rampal R; Qi J; Kleppe M; Patel HJ; Shah SK; Taldone T; Bradner JE; Chiosis G; Levine RL
Blood; 2014 Mar; 123(13):2075-83. PubMed ID: 24470592
[TBL] [Abstract][Full Text] [Related]
12. Pharmacobiological Approach for the Clinical Development of Ruxolitinib in Myeloproliferative Neoplasms.
Eliaçık E; Işık A; Aksu S; Üner A; Büyükaşık Y; Sayınalp N; Göker H; Özcebe OI; Haznedaroğlu İC
Turk J Haematol; 2015 Jun; 32(2):163-7. PubMed ID: 26316485
[TBL] [Abstract][Full Text] [Related]
13. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
14. New generation small-molecule inhibitors in myeloproliferative neoplasms.
Passamonti F; Maffioli M; Caramazza D
Curr Opin Hematol; 2012 Mar; 19(2):117-23. PubMed ID: 22227528
[TBL] [Abstract][Full Text] [Related]
15. Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangements.
Chase A; Bryant C; Score J; Haferlach C; Grossmann V; Schwaab J; Hofmann WK; Reiter A; Cross NC
Haematologica; 2013 Mar; 98(3):404-8. PubMed ID: 22875628
[TBL] [Abstract][Full Text] [Related]
16. Ruxolitinib reduces JAK2 p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study.
Vannucchi AM; Verstovsek S; Guglielmelli P; Griesshammer M; Burn TC; Naim A; Paranagama D; Marker M; Gadbaw B; Kiladjian JJ
Ann Hematol; 2017 Jul; 96(7):1113-1120. PubMed ID: 28456851
[TBL] [Abstract][Full Text] [Related]
17. Autophagy inhibition potentiates ruxolitinib-induced apoptosis in JAK2
Machado-Neto JA; Coelho-Silva JL; Santos FPS; Scheucher PS; Campregher PV; Hamerschlak N; Rego EM; Traina F
Invest New Drugs; 2020 Jun; 38(3):733-745. PubMed ID: 31286322
[TBL] [Abstract][Full Text] [Related]
18. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Atallah E; Verstovsek S
Expert Rev Anticancer Ther; 2009 May; 9(5):663-70. PubMed ID: 19445582
[TBL] [Abstract][Full Text] [Related]
19. JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy.
Barosi G; Klersy C; Villani L; Bonetti E; Catarsi P; Poletto V; Campanelli R; Impera S; Latagliata R; Viarengo G; Carolei A; Massa M; Musso M; Crescimanno A; Gale RP; Rosti V
Leukemia; 2016 Aug; 30(8):1772-5. PubMed ID: 26975727
[No Abstract] [Full Text] [Related]
20. Pharmacologic management of myelofibrosis.
Leung M; Highsmith K; Rexwinkle A
J Oncol Pharm Pract; 2017 Dec; 23(8):591-601. PubMed ID: 27672139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
